Pay in 4 interest-free payments of $7.40 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
Top-line trial numbers: Weight-Loss Endpoints by Dose Cohort (Phase 2, 48 weeks) Mean body-weight reduction from baseline at the 48-week primary endpoint: Secondary endpoint magnitudes at the 12mg cohort: 41% mean reduction in fasting insulin
This leads to changes in how your cells work and express genes [4]
After 24 weeks, all groups taking retatrutide saw significant weight loss compared to the placebo group (1.6% average weight loss): 7.2% for those taking 1 mg 11.8% for those taking 4 mg after starting with 2 mg 13.9% for those taking 4 mg after starting with 4 mg 16.7% for those taking 8 mg after starting with 2 mg 17.9% for those taking 8 mg after starting with 4 mg 17.5% for those taking 12 mg after starting with 2 mg After 48 weeks, patients taking retatrutide experienced even more substantial losses: 8.7% for those taking 1 mg 16.3% for those taking 4 mg after starting with 2 mg 17.8% for those taking 4 mg after starting with 4 mg 21.7% for those taking 8 mg after starting with 2 mg 23.9% for those taking 8 mg after starting with 4 mg 24.2% for those taking 12 mg after starting with 2 mg The researchers also reported that 100% of patients taking 8 mg or 12 mg saw a weight reduction of at least 5%, and 7583% had a weight reduction of 15% or more
Extracellular acidosis and mTOR inhibition drive the differentiation of human monocyte-derived dendritic cells
